PRME News and Press, First Trust Heitman Global Prime Real Estate ETF From 04/29/24

First-Ever Open IND for Prime Editing Technology PM359 is Prime Medicine’s Ex Vivo Product Candidate Designed to Correct a Prevalent Disease-Causing Mutation of CGD Initial Data Expected in 2025 CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, In...

-- Presentations include new preclinical data for PM359, further demonstrating ability of Prime Editors to efficiently, reproducibly and durably correct causative mutation of CGD; on track to enter clinical development in 2024, with initial data expected in 2025 -- -- Prime Medicine Co-...

2024-04-05 14:32:16 ET More on Markets AllianceBernstein spotlights demand shifts in the EV industry We're seeing new money come into Bitcoin – TD Securities Treasury yields continue to climb, see what SA analysts have to say AllianceBernstein warns of...

2024-04-02 17:00:03 ET David Nierengarten from Wedbush issued a price target of $12.00 for PRME on 2024-04-02 16:15:00. The adjusted price target was set to $12.00. At the time of the announcement, PRME was trading at $6.32. The overall price target consensus is at $21.0...

2024-03-25 02:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-14 14:44:39 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips A short squeeze is a financial phenomenon where rapidly increasing prices force short sellers to buy back stocks, pushing prices even higher. This situation often arises from a large number of ...

2024-03-06 16:16:26 ET More on Metagenomi, Inc. Stocks To Watch: Eyes On Broadcom, Target, Costco, Rivian And Small Caps Metagenomi Begins Genetic Treatment IPO Rollout Moderna-backed Metagenomi sees stock fall 31% after $94M IPO Metagenomi prices initial off...

-- Maturing into clinical-stage company; on-track to file IND application or CTA for PM359 in 1H 2024, with initial data expected in 2025 -- -- Progressing broader portfolio across core areas of focus; expect to initiate IND-enabling activities in first liver and ocular disease progra...

CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in two upcoming conferences: ...

CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten upsized public offering of 22,560,001 shares ...